January 07, 2022

Purdue Pharma can appeal rejection of bankruptcy plan - PharmaLive

Purdue Pharma can appeal rejection of bankruptcy plan

NEW YORK, Jan 7 (Reuters) – A U.S. judge on Friday allowed Purdue Pharma to immediately challenge her rejection of legal protections for Sackler family members who own the OxyContin maker, and which were a major component of its bankruptcy reorganization plan.

U.S. District Judge Colleen McMahon’s ruling means Purdue will have another shot at keeping intact a $4.5 billion opioid litigation settlement at the heart of the company’s plan. She gave Purdue until Jan. 17 to file the appeal to the New York-based 2nd U.S. Circuit Court of Appeals.

McMahon reversed a bankruptcy judge’s order approving the deal in December. The settlement provides so-called nondebtor releases that shield the Sacklers against future opioid-related lawsuits.

Several states and the U.S. Department of Justice’s bankruptcy watchdog opposed the releases, saying the Sacklers should not be afforded such protections since they did not file for bankruptcy themselves.

McMahon said in Friday’s ruling that the appeal should be handled quickly “given the urgency of the opioid crisis and the importance of the issue to the resolution of this case.”

Purdue filed for bankruptcy in 2019 in the face of thousands of lawsuits accusing it and the Sacklers of fueling the opioid epidemic through deceptive marketing.

The Sacklers, who have denied wrongdoing, contributed the $4.5 billion to the settlement in exchange for the releases. Under Purdue’s reorganization plan,...

Read Full Story: https://www.pharmalive.com/purdue-pharma-can-appeal-rejection-of-bankruptcy-plan/

Your content is great. However, if any of the content contained herein violates any rights of yours, including those of copyright, please contact us immediately by e-mail at media[@]kissrpr.com.